Published in Evid Based Complement Alternat Med on June 30, 2014
The Natural Flavonoid Fisetin Inhibits Cellular Proliferation of Hepatic, Colorectal, and Pancreatic Cancer Cells through Modulation of Multiple Signaling Pathways. PLoS One (2017) 0.78
Effect of an ethanol extract of Descurainia sophia seeds on Phase I and II drug metabolizing enzymes and P-glycoprotein activity in vitro. BMC Complement Altern Med (2015) 0.75
The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician (2007) 2.74
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol (2001) 2.38
The human intestinal cytochrome P450 "pie". Drug Metab Dispos (2006) 2.31
Drug interactions in cancer therapy. Nat Rev Cancer (2006) 1.62
Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist (2006) 1.43
Flavonoids purified from Rhus verniciflua Stokes actively inhibit cell growth and induce apoptosis in human osteosarcoma cells. Biochim Biophys Acta (2005) 1.35
Mechanism of CYP2C9 inhibition by flavones and flavonols. Drug Metab Dispos (2008) 1.24
Fisetin: a dietary antioxidant for health promotion. Antioxid Redox Signal (2012) 1.10
Clinical features of 31 patients with systemic contact dermatitis due to the ingestion of Rhus (lacquer). Br J Dermatol (2000) 1.08
Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol (2004) 1.07
Flavonol-rich RVHxR from Rhus verniciflua Stokes and its major compound fisetin inhibits inflammation-related cytokines and angiogenic factor in rheumatoid arthritic fibroblast-like synovial cells and in vivo models. Int Immunopharmacol (2008) 1.03
Phenolic-rich fraction from Rhus verniciflua Stokes (RVS) suppress inflammatory response via NF-kappaB and JNK pathway in lipopolysaccharide-induced RAW 264.7 macrophages. J Ethnopharmacol (2006) 0.99
NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status. Asian Pac J Cancer Prev (2007) 0.96
Selective antiproliferative and apoptotic effects of flavonoids purified from Rhus verniciflua Stokes on normal versus transformed hepatic cell lines. Toxicol Lett (2005) 0.93
Anti-inflammatory effects of sulfuretin from Rhus verniciflua Stokes via the induction of heme oxygenase-1 expression in murine macrophages. Int Immunopharmacol (2010) 0.92
Inhibition of the PI3K-Akt/PKB survival pathway enhanced an ethanol extract of Rhus verniciflua Stokes-induced apoptosis via a mitochondrial pathway in AGS gastric cancer cell lines. Cancer Lett (2008) 0.92
Sulfuretin isolated from heartwood of Rhus verniciflua inhibits LPS-induced inducible nitric oxide synthase, cyclooxygenase-2, and pro-inflammatory cytokines expression via the down-regulation of NF-kappaB in RAW 264.7 murine macrophage cells. Int Immunopharmacol (2010) 0.92
Rhus verniciflua Stokes prevents cisplatin-induced cytotoxicity and reactive oxygen species production in MDCK-I renal cells and intact mice. Phytomedicine (2009) 0.91
Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol (2011) 0.90
Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol (2013) 0.89
Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents. Molecules (2014) 0.86
Drug interaction between complementary herbal medicines and gefitinib. J Thorac Oncol (2008) 0.86
Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China. Genet Mol Res (2010) 0.85
Selective cytotoxic effects on human cancer cell lines of phenolic-rich ethyl-acetate fraction from Rhus verniciflua Stokes. Am J Chin Med (2009) 0.84
Rhus verniciflua Stokes extract as a potential option for treatment of metastatic renal cell carcinoma: report of two cases. Ann Oncol (2010) 0.83
Successful outcome of advanced pulmonary adenocarcinoma with malignant pleural effusion by the standardized rhus verniciflua stokes extract: a case study. Explore (NY) (2009) 0.83
Rhus verniciflua stokes against advanced cancer: a perspective from the Korean Integrative Cancer Center. J Biomed Biotechnol (2011) 0.83
Anti-inflammatory and anti-nociceptive effects of the extract from Kalopanax pictus, Pueraria thunbergiana and Rhus verniciflua. J Ethnopharmacol (2004) 0.83
Flavonoids inhibit genetic toxicity produced by carcinogens in cells expressing CYP1A2 and CYP1A1. Mutagenesis (2002) 0.83
Shrinkage of gastric cancer in an elderly patient who received Rhus verniciflua Stokes extract. J Altern Complement Med (2010) 0.82
Role of CYP1A2 polymorphisms in breast cancer risk in women. Mol Med Rep (2012) 0.82
A case of recurred hepatocellular carcinoma refractory to doxorubicin after liver transplantation showing response to herbal medicine product, Rhus verniciflua Stokes extract. Integr Cancer Ther (2010) 0.82
Antioxidant activity of a Rhus verniciflua Stokes ethanol extract. Food Chem Toxicol (2001) 0.81
Efficacy and safety of standardized allergen-removed Rhus verniciflua Stokes extract in patients with advanced or metastatic pancreatic cancer: a Korean single-center experience. Oncology (2011) 0.81
Herb-drug interactions in oncology. Clin Pharmacol Ther (2014) 0.80
Cytochrome P450 2C19 inhibitory activity of common berry constituents. Phytother Res (2010) 0.79
Adverse Interaction between Capecitabine and Warfarin Resulting in Altered Coagulation Parameters: A Review of the Literature Starting from a Case Report. Case Rep Med (2010) 0.78
Impact of Standardized Allergen-Removed Rhus verniciflua Stokes Extract on Advanced Adenocarcinoma of the Ampulla of Vater: A Case Series. Evid Based Complement Alternat Med (2013) 0.76